title: Reversal or nitroglycerin tolerance by the cGMP phosphodiesterase inhibitor zaprinast.
authors.affiliation: Department of Cardiovascular Pharmacology, Sterling Research Group, Rensselaer, NY 12144.
authors.forename: P J
authors.initials: PJ
authors.lastname: Silver
authors.forename: E D
authors.initials: ED
authors.lastname: Pagani
authors.forename: L
authors.initials: L
authors.lastname: de Garavilla
authors.forename: G S
authors.initials: GS
authors.lastname: Van Aller
authors.forename: M L
authors.initials: ML
authors.lastname: Volberg
authors.forename: P F
authors.initials: PF
authors.lastname: Pratt
authors.forename: R A
authors.initials: RA
authors.lastname: Buchholz
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D004361:Drug Tolerance; D066298:In Vitro Techniques; D008297:Male; D009126:Muscle Relaxation / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D005996:Nitroglycerin / Q000494:pharmacology*; D011688:Purinones / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains
chemical_list: D011688:Purinones; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D005996:Nitroglycerin; C011145:zaprinast